Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Radiolabelled Bivatuzumab in Head and Neck Cancer
NCT02204033Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 1999
- Primary completion
- Jun 2001
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
Phase 1, open-label trial of bivatuzumab in head and neck squamous cell carcinoma (HNSCC) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of patients with adverse events up to 10 weeks, Presence of human-anti-human-antibody (HAHA) and 16 more. Started Mar 1999; status: completed.
02
Drugs
bivatuzumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02204033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02204033.